Trial Profile
To evaluate the relationships between the serum concentration of Erlotinib and the effects and toxicities of them
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 May 2014
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Apr 2014 Planned number of patients changed from 26 to 20 as reported by University Hospital Medical Information Network - Japan.
- 19 Jan 2014 New trial record